The awards are designed to recognise successful implementation of quality improvement (QI) in veterinary practice, which can reduce avoidable errors, ensure practice is based on the best available evidence and, ultimately, save lives.
Entrants will need to demonstrate the impact that QI methods have had in their practice, such as increased efficiency, improved clinical or financial effectiveness, the development of a culture of continuous improvement, support in the use of evidence-based approaches, or a general bettering of excellence in care.
The awards are open to any member of a practice, including veterinary surgeons and nurses, practice managers, receptionists, locums, students, and more. You can also nominate a colleague, or vice versa.
Individual winners will get free tickets to an upcoming RCVS Knowledge event and be given a plaque pronouncing them a 'Knowledge Champion', while one team will scoop Knowledge’s 'Champion Practice' award.
RCVS Knowledge Executive Director Chris Gush said: "These awards are a great opportunity to celebrate the good work that is going on in practice and to highlight examples of quality improvement.
"I would encourage all – from quality improvement experts to QI beginners – to get involved and enter the awards."
The closing date to submit an application is 1st November 2018, allowing plenty of time for those interested in introducing a quality improvement initiative in their practice to do so and apply for the awards at a later date.
To learn more about QI and how you can get started, visit RCVS Knowledge's QI pages.
Alternatively, you can enter the awards here: https://knowledge.rcvs.org.uk/grants/available-grants/
Trilotab is licensed for the treatment of pituitary-dependent hypercortisolism (PDH) caused by an adrenocorticotrophic hormone (ACTH)-secreting pituitary adenoma, which accounts for 85% of spontaneous cases of Cushing’s, and for the treatment of adreno-dependent hyperadrenocorticism (ADH) caused by a cortisol-secreting adrenocortical tumour (ACT), which accounts for the remaining 15% of spontaneous cases1.
The new tablet is divisible into halves and quarters to facilitate dose adjustment and make administration easier.
Divided tablets remain stable outside of the blister packaging until the next dose is due, thereby avoiding wastage.
Trilotab tablets are chewable and chicken-flavoured to help improve treatment compliance.
They contain hydrolysed chicken flavouring so they can be prescribed for pets allergic to chicken.
Trilotab is administered once daily with food with a starting dose of 2mg trilostane/kg bodyweight.
The new tabs are available in three presentations: 10mg, 30mg, and 60mg presentations, which Virbac says should help practices reduce their dispensary stockholding.
Andrew Connolly, Marketing Director – UK & Ireland at Virbac, said: ‘The complex nature of Cushing’s syndrome in dogs can make it a challenging condition to manage for both the clinician and the pet owner.
"With the requirement for lifelong treatment, it is our hope that Trilotab’s easy administration and simplified dosing protocols will genuinely help to improve the lives of dogs affected by the disease, whilst making the clinician and pet owner’s lives just a little bit easier too!"
Reference
The intranasal vaccine can be administered to calves from one week old. It reduces the clinical signs of respiratory disease and viral shedding from infection with Bovine Respiratory Syncytial Virus (BRSV) and Parainfluenza-3 Virus (Pi3V).
MSD says that no other UK-licensed BRD vaccine can be administered earlier in life, and claims the vaccine delivers the fastest on-farm protection, with an onset of immunity after administration of 5 days for BRSV and 7 days for Pi3V. Duration of immunity is 12 weeks for both viruses.
MSD Animal Health livestock veterinary adviser Dr Kat Baxter-Smith said: "Having this early life calf pneumonia vaccine available in single dose vials will give farmers more practical leeway to be able to vaccinate vulnerable young calves from as young as a week of age, rather than delaying administration until a batch of calves are available. We know that early-age protection of young calves through intranasal vaccination can help prevent pneumonia and positively impact a beef or dairy calf’s productive future".
The new single dose vials are supplied in packs of five, complementing the five dose vials already available.
For further information, contact your MSD account manager.
The company says more and more CT scanners are being used in general practice, but many teams have been telling them they're not sure if they're using their scanner optimally, or that only some of the team are confident in using it.
The online training aims help teams get the best diagnostic use of CT
The first of the sessions, on 15th June, will cover the indications and benefits of CT in small animal practice.
The second on 22nd June will look at how and when to perform CT reconstructions.
Manuel Pinilla, VetCT Supporting Radiologist and Director of Quality Assurance (pictured right), will be delivering the talks.
Manuel said: “We are seeing a rapid increase in the use of CT in first opinion practice.
"We know CT can provide vital diagnostic information in addition to the more traditional modalities of x-ray and ultrasound.
"However, it can be challenging to optimise the diagnostic capability.
"We’re keen to support veterinary teams to help them get the most out of their machine and do the best for their patients and the owners.”
To register for the training, visit: https://welcome.vet-ct.com/ctcpdwebinars
The study, published in Nature Scientific Reports, investigated the effect of culling in the first three licensed badger cull areas – Gloucestershire, Somerset and Dorset – using data from 2013 to 2017.
Gloucestershire and Somerset saw reductions in bTB incidence rates in cull areas relative to comparison areas of 66 per cent and 37 per cent respectively after four years. In Dorset, there was no change in incidence rates in cull areas relative to comparison areas after two years, but incidence dropped by 55 per cent in the same period in the 2km buffer zone around the edge of the cull area. Matched comparison areas were similar but not identical.
James Russell, BVA Junior Vice President said: "These findings are encouraging and offer further evidence that badger culling can result in significant reductions in the number of new cases of TB in cattle. However, they come with the caveat that the data only relates to the first three cull areas, and the variability within these alone makes it too early to draw firm conclusions that culling will reduce incidence significantly in all 40 areas where it is now taking place.
"BVA’s expert working group is currently considering all aspects of disease control looking at cattle testing, removal of reactors, compensation and control in other farmed animals as well as the culling and vaccination of badgers. The group will consider this additional evidence as we develop our new policy on bTB.
"We continue to support a comprehensive and evidence-based approach to tackling bTB, including the use of badger culling where there is a demonstrated need and where it is done safely, humanely and effectively as part of a comprehensive strategy.
"The best way of halting the spread of this devastating disease is enhancing our understanding of bTB and applying that evidence to the eradication process.”
Gabbrovet Multi is the first and only ready-to-use solution licensed to treat both cryptosporidium and E.coli diarrhoea in calves.
The company highlights a study of 334 calves with severe diarrhoea, where those receiving Gabbrovet Multi showed a faster and more effective response than those given halofuginone1.
Harry Walby, ruminant veterinary advisor at Ceva Animal Health, said: “Gabbrovet Multi is the first and only ready-to-use solution for the convenient treatment of both cryptosporidium and E.coli, two of the most common causes of neonatal scour in calves."
Gabbrovet Multi can be administered in milk or water.
It is available with a dosing cap and comes in 250ml, 500ml or 1l presentations.
Gabbrovet Multi also treats gastro-intestinal infections caused by E.coli in pigs.
For further information, contact your local Ceva Animal Health territory manager or email cevauk@ceva.com.
References
Elanco Animal Health has highlighted the results of a new study1 which concludes that Duvaxyn IE-T Plus stimulates a highter protective antibody response than four other equine influenza vaccines commercially available in Ireland.
The trial compared the antibody responses of unvaccinated Thoroughbred weanlings following primary vaccination with Duvaxyn IE-T Plus, Equilis Resequin, Equip FT, Equilis Prequenza Te and ProteqFlu Te.
In addition, following the first vaccination, 43% of the weanlings failed to seroconvert. However, amongst those vaccinated with Duvaxyn IE-T Plus a 100% response rate was observed. The failure rate amongst vaccines other than Duvaxyn IE-T Plus ranged between 7.7% and 78.6%. By the time of the third vaccination (31 weeks after the first) all horses had responded to vaccination.
The study, conducted by the Irish Equine Centre in Johnstone, the Department of Life Sciences at the University of Limerick and the Department of Statistics at Trinity College in Dublin, involved 66 unvaccinated Thoroughbred weanlings on four different stud farms. Following primary vaccination (V1, V2 and V3) with the five vaccines antibody responses were monitored for six months post V3 by single radial haemolysis. Elanco says that the correlation between SRH antibody levels and protection has been well-established and accepted2.
Elanco also highlights a recent study3 which it says demonstrated the ability of Duvaxyn IE-T Plus equine influenza vaccine to cross protect against A/equi-2/Richmond/1/07 (H3N8) two weeks after a two dose primary course. The company says that this is believed to be the first demonstration of cross protection by a current UK equine influenza vaccine against a Florida sub-lineage clade 2 reference strain.
Anna Jackson, national veterinary manager for Elanco Companion Animal Health said: "Most studies carried out by vaccine companies take place under controlled conditions that are optimal for effective vaccination. This latest study shows how well Duvaxyn IET plus stimulates immunity under field conditions against both vaccinal and non-vaccinal strains. Importantly, all the weanlings vaccinated with Duvaxyn seroconverted after the first vaccination, conferring earliest and most reliable protection for these vulnerable animals."
For further information please contact your local Elanco Companion Animal Health key account manager or phone 01256 779881.
References:
whatstherisk.co.uk has been created for all practice staff and contains advice from parasitologists Ian Wright and Eric Morgan.
Topics include advice on practical risk assessments, how risk-based prescribing can work with health plans as well as how to get owners involved to make risk assessment and personalised prescribing quicker and simpler.
Boehringer says that all the materials and advice have been developed in line with RCVS Practice Standards and the BVA's guidance on the responsible use of parasiticides.1,2
Sharron Woods, NexGard brands Franchise Manager said: “With knowledge about parasitic risk low among dog owners, alongside increasing scrutiny on the potential overuse of parasiticides, we’re delighted to be at the forefront of supporting vets, pet owners and the wider industry in driving best-practice risk assessment and responsible parasite control."
Pets at Home has announced the acquisition of the joint venture practice business, Vets4Pets, adding 93 stand-alone veterinary practices to the 116 in-store practices it already operates under the Companion Care brand.
Providing veterinary and grooming services to consumers is seen as the way for the retailer to overcome competition from the Internet.
Nick Wood, CEO of Pets at Home said: "The expansion of our veterinary business is a key element of our growth strategy for Pets at Home, providing additional services to our customers within our stores or close to our customers' homes. The acquisition of Vets4Pets is an important step in the delivery of this strategy. Vets4Pets is highly complementary to Companion Care, sharing fundamental beliefs and values, and is an excellent strategic fit for Pets at Home. I am delighted that Peter Watson has agreed to stay with the business. His knowledge and experience will be invaluable as we continue to build our veterinary business with both stand-alone and in-store practices. He will work closely with Jane Balmain, the Managing Director of our Companion Care business as we integrate the two businesses."
Peter Watson, Founder and CEO of Vets4Pets said: "Pets at Home holds a unique place in the retail landscape, built on a strong identity and a real passion for people and pets. It is clear to me that Nick and his team have a similar vision for their veterinary business. I'm delighted to be working with Nick to continue to expand the veterinary business by offering attractive joint venture opportunities for vets in stand alone locations to complement the offering in Pets at Home stores."
Companion Care MD, Jane Balmain added: "Companion Care and Vets4Pets each enjoy a strong reputation among both vets and customers. Both businesses have a common business model, offering joint venture partnerships with vets. I am looking forward to working alongside Peter as we bring the businesses together, continue to expand our joint venture partnerships and accelerate our growth."
Vets4Pets' UK operational centre will remain in the East Midlands, with its support functions being split between Companion Care's operation in Oxfordshire and Vets4Pets' Guernsey office.
Boehringer Ingelheim Vetmedica has launched Pexion (imepitoin) a novel treatment for canine idiopathic epilepsy.
Canine epilepsy can affect up to 5% of dogs6. In most dogs diagnosed with idiopathic epilepsy no underlying cause for the seizures can be found. While the condition can affect any dog, it is more common in young (one to five year old), purebred dogs such as Labradors, Golden Retrievers, German Shepherds, Boxers, Vizlas, Beagles, English Springer Spaniels, Irish Setters, Poodles and Dachshunds.
Boehringer says Pexion has a highly targeted mode of action1-3 to suppress a dog's seizures. It starts to work within a few hours and reaches steady state within three days4,5. Boehringer claims this will make it easier to stabilise epileptic patients. It also says there is no evidence of hepatotoxicity or liver-associated enzyme elevation, so repeated blood tests for liver enzymes or therapeutic levels are no longer required.4,5
Pexion is available in 100 mg and 400 mg tablets. The tablets are white, scored and divisible in half. Both tablet strengths are available in 100 tablet packs from veterinary wholesalers.
Jemima Mead, brand manager at Boehringer said: "Pexion is a ground-breaking new product which gives vets a new first-line treatment option for dogs with idiopathic epilepsy, improving the lives of newly diagnosed epileptic dogs and their owners by reducing the number of seizures and their impact on the patient's life".
To support the launch of the new product, Boehringer hosted an epilepsy webinar presented by neurologist Dr Holger Volk DVM PhD DipECVN FHEA MRCVS, recognised RCVS and European Specialist in Veterinary Neurology. The webinar is now available on demand at www.bi-academy.co.uk.
For further information on Pexion visit www.pexion.co.uk, contact your local Boehringer Ingelheim territory manager or telephone +44 (0)1344 746959.
Virbac has launched Prinovox, a new prescription-only spot-on ectoparasiticide for dogs and cats.
The company says the new product contains the same combination of Moxidectin and Imidacloprid as the market leader, but is offered with a unique and innovative pet owner engagement programme to help practices build loyalty, increase compliance and to encourage repeat purchase.
In dogs Prinovox is licensed for the treatment and prevention of lungworm; for the treatment and prevention of fleas and also for lice, mites, heartworm and roundworms. In cats, the licence covers fleas, mites, roundworm and heart worm. It can also be used for fleas and heartworm in ferrets.
Prinovox is available in six presentations to suit all weight ranges and in packs of four pipettes. The packaging uses the Blippar platform which owners can use to 'blip' interactive icons on the product's packaging with their smartphone to get more information on Prinovox, including a video on how to use it, a reminder system and a game.
In addition, the Prinovox support package includes:
Virbac's Head of Marketing Companion Animal, Simon Boulton MRCVS said: "We see the launch of Prinovox as a gamechanger. The ectoparasiticide market is one of the largest and most competitive in our industry and we are the first company to offer a product with the same efficacy as the market leader for all indications.
"We've gone one step further by increasing the value of the product to practices by developing a comprehensive parasite protection support package which harnesses the latest technology and consumer preferences for receiving information. We believe the efficacy of Prinovox, combined with the innovative support package we're offering, will make it a highly attractive product for practices and owners and we've been delighted at the feedback we've received so far."
Forte developed the new solution alongside Professor Gayle Hallowell, Professor of Veterinary Internal Medicine and Critical Care at the School of Veterinary Medicine and Science, University of Nottingham.
The company says Hydrafast delivers ideal levels of sodium and glucose. It also contains glycine, an amino acid, acetate, propionate and citrate.
Professor Hallowell said: “This new ORS formula for calves is both practical and research-based, and should address what we know calves need when they have diarrhoea. It provides nutrition as well as an optimal electrolyte balance.”
Hydrafast comes in sachets of 133g. Each box of Hydrafast contains 24 sachets.
Hydrafast is available now from all major veterinary wholesalers, or direct from Forte Healthcare Ltd.
For more information contact your Forte Territory Manager, email enquiries@fortehealthcare.com or visit: www.fortehealthcare.com/product/hydrafast/
The company says its new design is modular, allowing veterinary practices to customise kennels to their requirements now, and then upgrade them and add components as their needs change over time.
Options include dimmable daylight lighting or Casco Pet’s DRC Lighting System with three modes: Daylight (white), Recovery (red), and Cleaning (blue UVA), built-in thermostatically controlled heat mats, an illuminated glass whiteboard for easy recording and viewing of patient notes, integrated IV stand and pump holders, an internal ceiling vent and ventilation kit and an integrated plug socket and USB port .
Matthew Bubear, CEO, Casco Pet, said: “Our new generation of WellKennels, which have been designed to meet the dynamic demands of modern veterinary practices, allow practitioners to elevate the care they provide today while ensuring sustained adaptability for the needs of tomorrow."
WellKennels are certified by the International Society of Feline Medicine and are part of FearFree’s Preferred Product Program, the global initiative dedicated to preventing and alleviating fear, anxiety and stress in pets.
The new WellKennels will be unveiled at the London Vet Show, ExCel London, 16-17 November, on Stand H35.
https://cascopet.com/uk/products-and-services/veterinary
The new, four storey, architecturally-designed clinic is full of natural light and includes calming and spacious staff breakout areas.
By combining a beautiful work environment with seamless technology, the company believes it can transform working conditions and job satisfaction for vet teams.
On the tech side, the Creature Comforts has created a proprietary app which allows triage to be handled online and for staff to work flexibly.
The company says the app also reduces the administrative burden, a contributory factor for staff burnout.
Creature Comforts says most clients subscribe at a cost of £20 per pet per month, giving them unlimited consultations, instant bookings and live chat via the app (as well as annual vaccinations and discounted routine treatments).
This should mean animals are seen more frequently, and conditions can be identified and treated earlier.
Memberships will be capped to control vet team caseload and to ensure a good customer experience.
The company is also addressing Competition and Markets Authority concerns, with prices for routine treatments listed on its website, upfront estimates for procedures, and a business model hinged on unlimited access to expertise (i.e. consultations, instant in-app bookings and live chat) at no extra cost for subscribed members.
Creature Comforts says its vet team benefits from a share of their clinic’s profits, above industry-standard pay, compensated overtime, a well-balanced staffing ratio, manageable working hours and scheduled breaks.
Dr Russell Welsh, COO and co-founder of Creature Comforts, said: “It’s an incredible feeling to see a plan come together in a sector that’s so ripe for transformation.
"We want to bring the passion, joy and fun back to our profession, and this is an opportunity to do things differently and vastly better, with a fresh and carefully-considered business model founded on the principles of health and happiness.
"This is vet care as it should be."
https://www.creaturecomforts.co.uk
The Federation of European Companion Animal Veterinary Associations (FECAVA) has announced the online publication of the Winter edition of its journal, EJCAP, which leads on responsible use of antibiotics and is now available free to all members of the veterinary profession.
The latest edition also features articles about indoor ferrets and hyperadrenocorticism, elderly cats and osteoarthritis, and correcting a malocclusion.
As a result of a unanimous decision by the FECAVA Council in October, the journal is now freely available to all veterinary practitioners, students and nurses throughout Europe.
To access the journal, visit: http://ejcap.fecava.org
Speakers include Prof. Jo Dukes McEwan, Head of Service, Professor in Small Animal Cardiology (University of Liverpool), Doctor Jennifer Schissler, Veterinary Dermatologist, Best Friends Animal Hospital & Urgent Care Unit (US), and Doctor Pascal Prélaud, Dermatologist, CEO ADVETIA Vet Hospital Center (France).
Participants will also be able to access to an immersive experience, the Vet Symposium Village, which includes the Live Stage, Vet Lab, Clinic Lounge, and Innovation Hub, all offering exclusive videos and lectures.
The event will be translated into Chinese, French, Spanish, Italian, Portuguese, Russian, and German, and a replay of the event will be available until the end of the year.
Dr. Jennifer Welser, Chief Medical Officer, Mars Veterinary Health, said: “It’s more critical than ever for pet professionals from various countries, fields, and perspectives to meet and share their knowledge.
"I look forward to participating in the Vet Symposium and speaking with my peers on topics ranging from mental health to advancements in quality medical care and retaining veterinary talent.”
https://digital-vetsymposium2022.com/
MSD says the new license claim means the vaccine combines the broadest calf scour protection available with unique user convenience.
MSD Animal Health livestock veterinary adviser Dr Kat Baxter-Smith said: “When correctly administered as a single 2ml intramuscular dose to pregnant cattle 12-3 weeks prior to calving, Bovilis Rotavec Corona boosts antibodies in colostrum for rotavirus, coronavirus and now both E.coli F5 (K99) and F41.
"Calves gain protection against these infectious scour pathogens by drinking the fortified colostrum from their vaccinated mothers.
“Bovilis Rotavec Corona also contains the most prevalent rotavirus strain in Europe2, which minimises the chances of a calf scour protection breakdown due to differences between vaccine antigens and the ubiquitous antigens on farm3.”
Kat added: "Vet, RAMA and farmer feedback suggests the wide vaccination window (12-3 weeks pre-calving) and the fact that an opened bottle of vaccine lasts for up to 28 days are particularly useful practical benefits in a mix of both dairy and beef suckler systems.”
Bovilis Rotavec Corona is available in 5, 20 and 50-dose packs from both veterinary professionals and the agricultural merchant trade.
MSD Animal Health has obtained regulatory approval in 21 European countries, including the UK, for Cobactan LA 7.5% (cefquinome) - a new-generation, injectable antimicrobial for the treatment of swine respiratory disease (SRD).
Raul Berro DVM, global marketing director swine at MSD Animal Health said: "Cobactan LA 7.5% is a long-acting version of our highly effective Cobactan 2.5%. Its longer duration of action means greater compliance for swine producers with fewer injections and less stress to the animals, without sacrificing performance."
According to the company, the long-acting antibiotic formulation is effective against three major SRD pathogens in growing and finishing pigs - Actinobacillus pleuropneumoniae, Haemophilus parasuis and Pasteurella multocida. Considered the most important threat to the swine industry worldwide, SRD causes increased mortality, decreased weight gain and increased feed consumption.
Cobactan LA 7.5% requires two intramuscular injections 48 hours apart, compared to Cobactan 2.5%, which requires three daily injections. The recommended dose rate is 1 mL (3 mg cefquinome) per 25 kg bodyweight. The product isavailable in 50-ml, 100-ml and 250-ml glass vials.
Raul aded: "COBACTAN LA 7.5% also has a short withdrawal period of seven days. This makes the injectable product also safe to use throughout the finishing period for the treatment of SRD."
MSD adds that the use of COBACTAN LA 7.5% should be according to established responsible use guidelines and strictly according to the label instructions where specific restrictions apply to this class of antibiotics.
For more information, contact your local MSD Animal Health representative or go to www.msd-animal-health.com.
Phil Kenward from Farm Vets South West in Bridgewater, Somerset has won a bottle of port from the Veterinary Benevolent Fund for submitting the best practical veterinary tip.
The tip was:
"Do not allow the owner's diagnosis of his problem to worry or influence you before you examine the animal yourself."
The competition was run to celebrate the launch of The Pocket Book of Tips For Practising Vets which can be ordered on-line from the Vetlife website to raise funds for the VBF charity.
Lydia Brown, President of the VBF, said: "This book has been a monumental effort by six mixed practice vets, to both share their experience with the profession and to provide very welcome funds for the veterinary profession's own charity, the VBF. We are currently raising money for the new Vet Helpline e-mail support service which will launch at the end of the year so we are extremely grateful to everybody concerned for all their efforts."
Canaural contains fusidic acid, framycetin and nystatin for their antibacterial and antifungal effects against the most common organisms associated with otitis externa.
Fusidic acid has skin penetrating properties and is active against staphylococci and streptococci1. Framycetin is active against Gram negative species. Dechra says the combination of the two provides an enhanced antibacterial effect on the most common bacterial cause of canine otitis2.
Nystatin is active against malassezia and prednisolone helps to provide anti-inflammatory and anti-pruritic action.
Dechra Brand Manager Carol Morgan said: “The reintroduction of Canaural to the veterinary treatment market means that once again veterinarians have this reliable and effective treatment available to tackle one of the most common canine complaints.
"Canaural is a tried and tested product and a recent study showed that fusidic acid is highly efficacious against both methicillin sensitive and methicillin resistant strains of Staphylococcus pseudintermedius3. Canaural remains as relevant today as it has ever been."
Canaural comes in 15 ml and 25 ml bottle sizes and is now available in veterinary wholesalers.
Invicta Animal Health has announced its appointment as exclusive veterinary distributor in the UK for Chloraprep, a licensed human product for cutaneous antisepsis, prior to invasive procedures.
Invicta says Chloraprep is a single use, easy to apply, sterile system, available in a variety of sizes and in clear and tinted versions to enhance the visibility of the area requiring antisepsis, for instance, prior to surgery.
The sterile solution is maintained in a glass ampoule inside a protective outer case and, to prevent contamination, the patented design ensures users don't come into contact with either the contents or the patient's skin.
Rob Watkins, Managing Director of Invicta, said: "Most surgical site infections (SSI's) are the result of contamination from a patient's own skin flora1, a fact which highlights the importance of thorough and effective preparation of the skin as a proactive way to minimise the incidence of SSI's in patients."
According to the company, research has shown that Chloraprep, which contains 2% chlorhexidine and 70% isopropyl alcohol, has demonstrated significantly better antimicrobial activity than other combinations2.
Invicta says the way in which the solution is applied to the skin is as important as the solution itself. Studies show that the most effective way to apply Chloraprep is with a back and forth scrubbing movement because this gives a lower microbial count on the skin than using other application methods3. Once applied, Chloraprep is active in 30 seconds and is effective for up to 48 hours4.
Rob said: "The majority of UK hospitals and the Blood Transfusion Service already use Chloraprep and we are pleased to make this available under the provisions of the cascade."
He added: 'The veterinary nurses I've spoken to love this product, because they're fed up of immersing their dry, cracked hands in disinfectant!'
For further information, please contact Invicta Animal Health on 01403 791313 or email the company at mail@invictavet.com.
1. Florman S, Nichols RL. Am J Infect Dis 2007; 3: 51-61.2. Hibbard JS. J Infus Nurs 2005; 28: 194-207.3. Rosenthal K. Nurs Manage 2006; April: 55-66.4. Garcia R et al. Abstracts of the IDSA 40th Annual Meeting 2002; Abs 418.
Invicta Animal Health has announced the launch of Ocuvance, a nutritional supplement to support ocular health in dogs and cats.
The company says Ocuvance is formulated to provide an antioxidant complex supporting and maintaining the health of eyes. The tablets contain lutein, a xanthophyll pigment found within the eye. They also contain anthocyanosides derived from bilberry extract to support rhodopsin production. The formulation also contains vitamins C and E, zinc and selenium.
Ocuvance is presented in packs of 30 scored tablets; sufficient for a one month supply for the average sized dog.
Rob Watkins, Managing Director of Invicta, said: "We are delighted to make Ocuvance available to veterinary surgeons in the UK. A recent veterinary study1 has shown there can be significant ophthalmic benefits of antioxidant supplementation.
We carefully formulated Ocuvance to provide a range of high quality ingredients to maintain normal visual function whilst still being affordable for owners”.
Ocuvance is now available from all veterinary wholesalers.
The legislation will come into effect from May 2018, at which point businesses will have six months to comply. The penalty for failing to comply will be an enforcement notice to the business or prosecution.
In August 2017, the Secretary of State launched a consultation on the plans to deliver a manifesto commitment for CCTV to be required in every slaughterhouse in England in all areas where live animals are present, with unrestricted access to footage for Official Veterinarians.
A summary of responses published in November showed that of almost 4,000 respondents, more than 99% were supportive of the plans.
Environment Secretary Michael Gove said: "We have some of the highest animal welfare standards in the world and want to cement our status as a global leader by continuing to raise the bar.
"Introducing compulsory CCTV cameras in slaughterhouses is a further demonstration to consumers around the world that as we leave the EU, we continue to produce our food to the very highest standards.
"The previous reaction to the consultation highlighted the strength of feeling among the public that all animals should be treated with the utmost respect at all stages of life and be subject to the highest possible welfare standards."
The proposals will also give the Food Standards Agency’s (FSA) Official Veterinarians (OVs) unfettered access to the last 90 days of footage to help them monitor and enforce animal welfare standards.
BVA President John Fishwick said: "Mandatory CCTV in all areas of slaughterhouses will provide an essential tool in fostering a culture of compassion that could help safeguard animal welfare.
"We commend the Government’s commitment to provide Official Veterinarians with unrestricted access to the footage, which the veterinary profession has long been campaigning for.
"It is vets’ independence and unique qualifications that help ensure the UK will continue to have the highest standards of animal health, welfare and food safety post-Brexit."
Photo: Lititz, Pennsylvania. Hoisting a slaughtered steer in Benjamin Lutz's slaughterhouse, 1942. Wikipedia.
The relevant section of the Government advice states: "This [key worker status] includes those involved in food production, processing, distribution, sale and delivery, as well as those essential to the provision of other key goods (for example hygienic and veterinary medicines)."
The RCVS/BVA statement, which is intended to help veterinary surgeons decide whether or not they can claim ‘key worker’ status and ask for their children to continue to be taken into schools, reminds veterinary surgeons to consider the wider societal picture and ensure that they only claim ‘key worker’ status if absolutely necessary.
The statement also stresses that the RCVS Code of Professional Conduct responsibility of the veterinary surgeon to take steps to provide 24-hour emergency first aid and pain relief to animals according to their skills and the specific situation continues, and veterinary practices will need to continue to carry out this work. It is important that animal owners are able to focus on their own health, and not need to worry about their pets. Both the RCVS and BVA believe that veterinary surgeons who are providing this essential work can be considered key workers.
The statement in full is as follows:
Veterinary surgeons as key workers in relation to school closures
RCVS and BVA appreciate that veterinary surgeons will feel a great deal of uncertainty at the present time, and that many will be facing considerable difficulties due to the closure of schools for most pupils.
The official government advice can be found here: https://www.gov.uk/government/publications/coronavirus-covid-19-maintaining-educational-provision/guidance-for-schools-colleges-and-local-authorities-on-maintaining-educational-provision.
The guidance emphasises that if children can be at home then they should be, in order to help to prevent the virus from spreading.
The government has granted key worker status by sector rather than profession. Some veterinary work will definitely fall into the ‘key worker’ category. RCVS and BVA are therefore providing some additional advice below, following consultation with the UK Chief Veterinary Officer:
SummaryAt this time the provision of public health and the maintenance of food production need to take priority, and veterinary surgeons working in these areas should be considered key workers.
Veterinary surgeons working in emergency care can also be considered key workers. This will not apply to every veterinary surgeon in clinical practice, and practices may need to consider rationalising their services to achieve this.
The guidance has been welcomed by both the BSAVA and BEVA. David Mountford, Chief Executive of BEVA said: "As veterinary professionals we are duty-bound to provide essential care, relieve suffering and protect the health of the public. Recognition as key workers in such circumstances is welcomed but we would encourage vets to only add to the burden faced by schools where animal welfare is at risk and all other avenues have been explored."
Last year Petplan received over 31,000 nominations across the five award categories: Practice of the Year, Vet of the Year, Vet Nurse of the Year, Practice Manager of the Year and Practice Support Staff of the Year.
The awards are judged by an independent panel which narrows the field to three finalists in each category, who are then invited to attend the awards ceremony.
The judges are looking for examples of exceptional levels of animal care, building and sustaining great relationships with colleagues and pet owners, and those who have gone above and beyond the call of duty.
James Barnes, Head of Sales & Partnerships at Petplan, said: “The Petplan Veterinary Awards provide the perfect opportunity to say thank you for the exceptional work carried out by members of the veterinary profession, whatever their field and wherever they’re based. The Petplan Vet Awards provide a great opportunity for both clients and colleagues to recognise the dedication and talent of veterinary professionals, teams and practices, right across the UK and say a particular thank you to those who have kept up the exceptional level of care even in the midst of a global crisis."
To nominate a colleague or your practice, visit www.petplan.co.uk before nominations close on 10th January 2022.